A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer

D. Ross Camidge, Eamon M. Berge, Robert C. Doebele, Marc S. Ballas, Thierry Jahan, Missak Haigentz, David Hoffman, James Spicer, Howard West, Pablo Lee, Ling Yang, Adarsh Joshi, Ling Gao, Sergey Yurasov, Alain Mita

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences